Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 906 of 6351
-
New blood test could spot hidden cancer cells that spread
Diagnosis Recruiting nowIn solid cancers, some more aggressive tumor cells actively detach from the primary lesion and then travel through the circulating compartment to reach distant organs and form micro-metastases. These circulating tumor cells (CTCs) that have become disseminated tumor cells (DTCs) …
Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Spinal stimulation and exercise may restore hand function in paralysis
Disease control Recruiting nowThe purpose of the current study is to evaluate whether a home-based, telehealth-supported intervention combining Blood Flow Restricted Exercise (BES) and Transspinal Stimulation (TS) will improve motor and functional abilities greater than BES+sham TS in persons with chronic, in…
Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can zapping cancer spots delay lung cancer progression?
Disease control CompletedThe purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared to systemic therapy.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug duo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis is a Phase 1b/2, open-label, dose escalation, dose expansion and dose optimization study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors. The study drug ADG126 is an …
Phase 1/2 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug cocktail targets Hard-to-Treat lymphoma
Disease control OngoingB-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants w…
Phase 2 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for lung cancer: immunotherapy without chemo shows promise
Disease control OngoingThis is a Phase III, single arm, multicenter study designed to evaluate the efficacy and safety of atezolizumab in high PD-L1 expression, chemotherapy-naïve, without a sensitizing EGFR mutation or ALK translocation patients with stage IV non-squamous or squamous NSCLC.
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for tough colorectal cancer? drug combo tested in Late-Stage trial
Disease control CompletedThe purpose of this China extension study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in adult Chinese participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of regoraf…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can a drug reverse immune shutdown in kids with sepsis?
Disease control CompletedThe GRACE-2 study is a prospective, multi-center, double-blind, randomized controlled trial of the drug GM-CSF vs placebo in children with sepsis-induced multiple organ dysfunction syndrome (MODS) who have immunoparalysis with mild to moderate inflammation.
Phase 3 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Quick therapy after rape may stop PTSD before it starts
Prevention OngoingRape is a common cause of post-traumatic stress disorder (PTSD) among women, as around 30-50% will develop PTSD in the aftermath of rape. A modified protocol based on Prolonged Exposure Therapy (mPE), has been developed, consisting of three to five once or twice weekly 60 minutes…
Sponsor: St. Olavs Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:30 UTC
-
New pill may help myeloma patients stay in remission longer after transplant
Disease control OngoingLenalidomide maintenance therapy following autologous stem cell transplant (ASCT) is standard of care for patients with multiple myeloma. However, nearly all patients will experience disease relapse and lenalidomide's toxicity profile leads to treatment discontinuation in 30% of …
Phase 2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New CAR t therapy targets tough lymphoma
Disease control Recruiting nowA Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Phase 1 • Sponsor: PeproMene Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Video diet coaching may cut heart risks after spinal cord injury
Disease control OngoingThis study will provide nutrition counseling via FaceTime on an iPad to persons with traumatic spinal cord injury (SCI) who are overweight or obese and are at least one-year post-injury. Nutrition counseling may help participants to develop eating behaviors that match the partici…
Sponsor: Santa Clara Valley Health & Hospital System • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Heart drug may shield patients from Post-Surgery heart injury
Disease control OngoingThis study is a multicentre, randomized controlled trial of ivabradine versus placebo.
Phase 3 • Sponsor: Jagiellonian University • Aim: Disease control
Last updated Jun 26, 2026 13:02 UTC
-
New cocktail of drugs shows early promise against tough bile duct cancer
Disease control CompletedTo evaluate the safety and tolerability of HAIC combined with donafenib and sintilimab in first-line treatment of unresectable ICC.
Phase 2 • Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Can AI learn to grade endoscopy quality from video?
Knowledge-focused Recruiting nowThe goal of this observational study is to establish a video/image library dataset of complete endoscopy or partial colonoscopy procedures for patients with rectal cancer or inflammatory bowel disease (IBD). With this video/image library, the aims are: * to develop and validate …
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New hope for advanced stomach cancer: drug cocktails under trial
Disease control OngoingThe purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of…
Phase 2 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could a daily glass of milk help ward off type 2 diabetes?
Disease control CompletedThe objective of the study is to determine the effect of dairy consumption on insulin sensitivity in overweight and obese adults with prediabetes. Men and women (30-65 y) will be recruited from the greater Montreal area. Upon screening, those with prediabetes will complete a 2-wk…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can Lab-Grown cartilage beads mend damaged joints?
Cure CompletedThe purpose of this study is to investigate the safety and feasibility of implanting autologous cartilage mini-grafts (or Cartibeads) into cartilage defects in the knee and ankle. Cartibeads are engineered from autologous articular chondrocytes (from the patient's own cartilage …
Phase 1 • Sponsor: Vanarix SA • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat kidney tumors
Disease control Recruiting nowThis phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug targets hard-to-treat cancers with missing MTAP gene
Disease control Recruiting nowThis is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC